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ABSTRAT
We recently performed 2 studies viewing the presence of Epstein–Barr virus (EBV) and high-risk human
papillomaviruses (HPVs) types 16, 18, 31, 33 and 35 in human breast cancer in the Syrian population.
Herein, we report that EBV and high-risk HPVs are co-present in breast cancer in Syrian women. Therefore,
and based on our previous studies and present data, we reveal that 35 (32%) of 108 cancer samples are
positive for both EBV and high-risk HPVs and their co-presence is associated with high grade invasive
ductal carcinomas (IDCs) with at least one positive lymph nodes, in comparison with EBV and high-risk
HPVs-positive samples, which are low to intermediate grade IDCs, respectively. Future studies are needed






Breast cancer is the most frequent cause of cancer-related death
among women. According to the World Health Organization
more than 508,000 deaths have been attributed to breast cancer
in 2011 (Global Health Estimates, WHO 2013). Actually, it is
well known that the majority of cancer deaths are the result of
metastasis, either directly due to tumor involvement of critical
organs or indirectly due to therapeutic resistance and the
inability of available therapy to control tumor progression. It is
estimated that approximately 20% of human cancers could be
linked to virus infection including Epstein–Barr virus (EBV)
and high-risk human papillomaviruses (HPV) especially types
16, 18 and 33, which cumulatively infect 80-90% of the popula-
tion worldwide.1,2 Accordingly, we have recently explored the
presence of EBV in a cohort of 108 breast cancer samples from
Syrian women by polymerase chain reaction (PCR) and Immu-
nohistochemistry (IHC) analysis using specific primers for
LMP1 and EBNA1 genes of EBV and a monoclonal anybody
for LMP1. In this context, it is important to mention that PCR
and IHC were largely used to detect the presence of onco-
viruses, particularly EBV and HPVs, in human cancers.1,2 Our
study revealed that 56 (51.85%) of the 108 samples are EBV
positive. Additionally, we reported that the LMP1 expression is
correlated with invasive breast cancer phenotype in more than
60% of breast cancer samples as opposed to »20% of in-situ
cancer tissues.3 Several other recent studies, including 3 from
the Middle East, showed clearly that EBV is present in 30-50%
of human breast cancer.4-8 Overall, these studies demonstrate
that EBV is present in human breast cancer; given the biologi-
cal actions of EBV-derived onco-proteins, it is quite possible
that it plays an important role in the initiation and/or
progression of this malignancy. This is based on our study as
well as recent investigations about the role of LMP1 and
EBNA1 onco-proteins of EBV in the initiation of epithelial-
mesenchymal transition (EMT) in human nasopharyngeal
cancer.9,10
On the other hand, it was pointed out that high-risk HPVs,
especially types 16, 18 and 33, can also be found in human
breast cancer;2 however, their precise role is not clear. There-
fore, we explored the role of E6/E7 onco-proteins of high-risk
HPV type 16, which is the most frequent HPV type worldwide.
We reported that the E6/E7 of HPV type 16 virus converts
non-invasive and non-metastatic breast cancer cells to an inva-
sive and metastatic phenotype; this was accompanied by an
overexpression of Id-1 gene,11 which is an important regulator
of cell invasion.12 Furthermore, we showed that E6/E7 onco-
proteins up-regulate Id-1 promoter activity in these breast can-
cer cells. In parallel, we found that HPV type 16 is present in all
examined invasive and metastatic breast cancer samples, from
Canadian women, and less frequently in in situ breast cancer as
opposed to normal mammary tissue.11 Therefore and based on
this investigation, we explored the incidence of high risk HPV
types 16, 18, 31, 33 and 35 in a cohort of 113 breast cancer sam-
ples from Syrian women by PCR and tissue microarray analy-
sis. Our study revealed that 69 (61.06%) of the 113 samples are
HPV positive, while 24 (34.78%) of them are co-infected with
more than one HPV type. Additionally, we showed that the
expression of the E6 onco-protein of high-risk HPVs is corre-
lated with Id-1 overexpression in the majority of invasive breast
cancer tissue samples.13 Earlier studies reported that high-risk
HPVs, especially types 16,18 and 33, are present in human
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breast cancer worldwide including the Middle East area, and
their presences are correlated with more aggressive pheno-
types.2,14 However, the presence of high-risk HPVs in human
breast cancer is still a subject of controversy since some investi-
gations were unable to detect HPVs in breast cancer as well as
normal mammary tissues.15,16
In this study, we explored the presence of EBV and high-risk
HPV (types 16, 18, 31, 33 and 35) together in breast cancer in
Syrian women by PCR and tissue microarray methodologies
using specific primers and monoclonal antibodies with all the
necessary controls, as described previously by our group.3,11,13
The use of these specimens and data in research was approved
by the Ethics Committee of the Faculty of Medicine of Aleppo
University.3,13 We report that 35 (32%) of the 108 samples are
positive for both EBV and high-risk HPVs (Table 1A). Based
on these data and our 2 earlier studies, we assessed the associa-
tion between the co-presence of these viruses and tumor
aggressiveness in our samples. We reveal that the co-expression
of the LMP1 and E6 onco-proteins of EBV and high-risk
HPVs, respectively, is associated with grade 3 invasive ductal
carcinoma (IDC) phenotypes (Table 1B and Fig. 1) with one or
more positive lymph nodes, in comparison with positive cases
of EBV alone or HPVs alone as well as negatives cases for both,
EBV and HPVs.3,11,13 while, it is important to mention that
EBV and HPVs positive cases were found to be low to interme-
diate grade IDC, respectively. In parallel, normal mammary tis-
sue and epithelial cells, which were used as controls, were
revealed negative for both EBV and HPVs.3,11,13
This is, to the best of our knowledge, the first report on the
co-presence of EBV and high-risk HPVs in human breast can-
cer and the relation of this co-incidence with cancer phenotype
in the Middle East area using 2 methodologies, PCR and IHC
(Table 1A and 1B). In fact, there are only 6 investigations
worldwide regarding the co-presence of EBV and high-risk
HPVs in human breast cancer: one from Australia,7 one from
Chile,17 one from China,18 2 from Taiwan19,20 and one from
the USA.21 Five among these studies confirmed the presence of
both EBV and HPVs in breast cancer using mainly PCR analy-
sis;7,17,18,19,20 however one study could not confirm this state-
ment in which the authors used RNA-Sequencing analysis to
detect the presence of these viruses.21 The presences of these
viruses vary from 2% to approximately 50% in breast cancer
with far lower frequency in benign and normal mammary
Table 1A. EBV and high-risk HPVs detection in human breast carcinomas. The co-
incidence of these viruses was found in 35 (32%) samples out of 108 examined by
PCR and IHC using specific primers for LMP1, EBNA1 and E6/E7 genes of EBV and
high-risk HPVs types (16, 18, 31, 33 and 35) as well as monoclonal antibodies for
E6 and LMP1, as described by our group.3,11,13 On the other hand, we noted that
EBV alone and high-risk HPVs alone are present in 56 and 66 of our samples,
respectively. The source of our samples is the pathology department of the Faculty
of Medicine of Aleppo University. These samples are collected from 2000 to 2007,
and they were chosen based on the pathology report, as breast cancer cases. All








(Paraffin samples) 108 PCR/IHC 35 32
These 2 methodologies, PCR and IHC, were used to detect the presences of EBV
and high-risk HPVs.
Table 1B. Presence of EBV and high-risk HPVs and their associations with high-
grade invasive ductal carcinomas. The co-presence of EBV and high-risk HPVs is
associated with grade 3 invasive ductal carcinoma and one or more positive lymph
nodes but not with In Situ breast cancer tissues (P D 0.0013). While, it is important
to highlight that EBV and HPVs positive cases were found to be low to intermedi-
ate IDC, respectively. On the other hand, the co-presence of EBV and high-risk
HPVs was assessed by PCR for LMP1 and EBNA1 and E6/E7 genes and confirmed
by IHC analysis of LMP1 and E6 expression using Tissue Microarray (TMA) method-
ology, as illustrated by our team;3,11,13 Two cores for TMA and 4 cores for DNA
extraction and PCR analysis were used from each samples; Normal mammary epi-
thelial cells and EBV and high-risk HPV-infected cells were employed as negative
and positive controls in our analysis.3,13
Breast cancer No of cases EBVC & HPVsC
Invasive 84 35/84
In situ 24 0/24
High grade Invasive ductal carcinomas
EBVC alone or HPVsC alone are low to intermediate grade Invasive ductal
carcinomas
Figure 1. Representative IHC revealing LMP1 and E6 expression of EBV and high-risk HPVs, respectively, in the same breast cancer sample which is high grade invasive
ductal carcinoma. Magnification is 100X. This analysis was performed using TMA methodology with all the necessary controls. Co-presence of EBV and high-risk HPVs was
confirmed by PCR using specific primers for LMP1, EBNA1 and E6/E7 genes.3,11,13
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tissues. Regarding the relation between the presence of these
viruses and histopathological parameters as well as survival, 2
studies found that the presence of EBV and HPVs could
enhance the grade of breast cancer and relapse-free survivals of
cancer patients.7,20 In our study, we demonstrated that the co-
presence of EBV and high-risk HPVs is associated with high-
grade invasive ductal carcinomas, with one or more positive
lymph nodes, in the Syrian women. We believe that LMP1 and/
or EBNA1 genes of EBV could cooperate with E5 and E6/E7
genes of high-risk HPVs to transform human mammary epi-
thelial cell and consequently initiate cancer development and
ultimately cancer metastasis via the EMT event, as mentioned
above and suggested in human oral cancer by our group;22 this
hypothesis is under investigation by our group. However, we
consider that further studies are necessary to elucidate the role
and pathogenesis of the co-presence of EBV and HPVs in
human breast malignancy; especially since EBV vaccine and
second-generation HPVs vaccine (nonavalent vaccine)23 are
presently under clinical trial studies and available, respectively.
Therefore, it is of great interest to gain a better understanding
of the association between EBV and HPVs co-infection and
breast cancer initiation and progression. This great advance-
ment could potentially limit breast cancer initiation as well as
its progression to a metastatic form thereby decreasing cancer-
related deaths. Ultimately, these data suggest that, for at least
some populations, breast cancer incidence and biology could
be eventually altered using public health programs that include
antiviral vaccines and therapies.
Finally, it is important to highlight that our investigation, in
the Syrian population, is limited to a small number of cases
located in a single region of Syria; therefore, it is essential to
perform other studies of large number of cases from different
regions of this country and ultimately several studies from the
Middle-East in general.
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